Why AI Alone Isn’t Enough for Oligonucleotide Discovery
A new analysis argues that oligonucleotide discovery remains too chemically and biologically complex to be solved by AI alone. The piece is a reminder that in some parts of biopharma, computational power still needs to be paired with deep domain knowledge and experimental iteration.
The argument that AI alone is not enough for oligonucleotide discovery lands at exactly the right moment in the field’s evolution. As more companies apply machine learning to RNA and nucleic-acid therapeutics, the temptation is to assume that better predictive models can replace the deeper scientific work of understanding delivery, stability, immune response, and target biology.
But oligonucleotides are a good example of where complexity resists simplification. These modalities are not just about selecting a sequence; they involve a dense set of constraints that span chemistry, pharmacology, and biology. AI can help navigate those constraints, but it cannot wish them away.
That makes this article especially valuable as a counterweight to the current market mood. The most productive use of AI in such domains may be as a partner to expert-driven design rather than a substitute for it. The companies that understand where models end and experimental science begins are likely to build more durable pipelines.
In the bigger picture, the piece reinforces a broader truth about AI drug discovery: the more complex the modality, the more important human judgment becomes. AI can narrow the search space, but it still needs a scientist to decide which tradeoffs are worth making and which ones could undermine the whole program.